Skip to content

Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma

Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03025854
Enrollment
600
Registered
2017-01-20
Start date
2017-01-31
Completion date
2023-01-31
Last updated
2020-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Brief summary

The purpose of this clinical research project is to explore potential biomarkers and validate the predictive and prognostic value of molecular signature in nasopharyngeal carcinoma.

Detailed description

Objectives: Primary: Evaluation of failure-free survival after three years of patients of nasopharyngeal carcinoma. Secondary: Evaluation of overall survival after three years of patients of nasopharyngeal carcinoma. Outline: This is a multicenter observational study. Tumor tissue specimens are obtained from the Sun Yat-sen University Cancer Center and Affiliated Hospital of Guilin Medical University. The samples are analyzed for biomarkers. The biomarkers are correlated with clinical outcomes (failure-free survival, overall survival, tumor response to treatment, distant metastasis, recurrence and death). The aim of the analysis is to explore potential biomarkers and validate the predictive and prognostic value of molecular signature in nasopharyngeal carcinoma. This will lead to the definition of risk groups and stratification of patients and will help to precision medicine of nasopharyngeal carcinoma.

Interventions

None listed

Sponsors

Guilin Medical University, China
CollaboratorOTHER
First People's Hospital of Foshan
CollaboratorOTHER
Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with newly histologically confirmed nasopharyngeal carcinoma * No evidence of distant metastasis (M0) * Written informed consent

Exclusion criteria

* Treatment with palliative intent

Design outcomes

Primary

MeasureTime frame
Failure-free Survival3 years

Secondary

MeasureTime frame
Overall Survival3 years

Countries

China

Contacts

Primary ContactJun Ma, M.D.
majun2@mail.sysu.edu.cn+86-20-87343469

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026